Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Lowers the risk of hospitalization for heart failure. ANDA 211312, held by Sandoz. Dapagliflozin.
As of Nov 15, 2026, ANDA 211312 (Dapagliflozin), held by Sandoz, was first approved by FDA on Apr 6, 2026, with 0 approved supplements and 0 published complete response letters.
First approved: Apr 6, 2026
Review: Standard
Supplements approved: 0
Complete response letters: 0
What It's For
From the FDA-approved label (Indications and Usage)
Dapagliflozin tablets are indicated:
To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors.
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use
Dapagliflozin tablets are not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.
Dapagliflozin tablets are not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m 2.
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters